Metastatic esophageal carcinoma is considered one of the worst prognosis cancers worldwide. The goals of treatment are usually symptoms palliation and possible life prolongation. In recent years, the field of immuno-oncology has shown promising treat- ment results and caused a paradigm shift in many types of cancer, as the response is quite long-lasting. Anti-programmed cell death 1 (anti PD-1) is one of the immuno-oncology drugs which has been investigated in many types of cancer and currently has been approved to be used in melanoma, lung cancer, kidney cancer and bladder cancer. We report a case of metastatic esophageal squamous cell carcinoma which had been heavily pretreated but presented an almost complete response to the anti PD-1, pembrolizumab.
immunotherapy,anti PD-1 blockage,pembrolizumab,esophagus,metastatic cancer